PubMed

SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.

Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group.

Diabetes Care. 2008 Nov;31(11):2169-76. Epub 2008 Aug 4.PMID: 18678611 [PubMed - indexed for MEDLINE]Related articlesFree article

[Pharmacological therapy of obesity]

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian. PMID: 18773755 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A.

Diabetes Care. 2008 Feb;31 Suppl 2:S229-40.PMID: 18227491 [PubMed - indexed for MEDLINE]Related articlesFree article

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

Hollander P.

Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S29-32.PMID: 17296341 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group.

Lancet. 2006 Nov 11;368(9548):1660-72. Erratum in: Lancet. 2006 Nov 11;368(9548):1650. PMID: 17098084 [PubMed - indexed for MEDLINE]Related articles

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen AJ.

J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. Review.PMID: 18426513 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators.

JAMA. 2008 Apr 2;299(13):1547-60. Epub 2008 Apr 1.PMID: 18387931 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group.

JAMA. 2006 Feb 15;295(7):761-75. Erratum in: JAMA. 2006 Mar 15;295(11):1252. PMID: 16478899 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.

Després JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):416-23. Epub 2008 Dec 26.PMID: 19112166 [PubMed - indexed for MEDLINE]Related articles

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.

Diabetes Obes Metab. 2003 May;5(3):180-8.PMID: 12681025 [PubMed - indexed for MEDLINE]Related articles

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group.

Lancet. 2005 Apr 16-22;365(9468):1389-97. Erratum in: Lancet. 2005 Jul 30-Aug 5;366(9483):370. PMID: 15836887 [PubMed - indexed for MEDLINE]Related articles

Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.

Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF; ACTOL Study Investigators.

J Clin Psychopharmacol. 2008 Jun;28(3):317-24.PMID: 18480689 [PubMed - indexed for MEDLINE]Related articles

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group.

N Engl J Med. 2005 Nov 17;353(20):2121-34.PMID: 16291982 [PubMed - indexed for MEDLINE]Related articlesFree article

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.

Diabetes Care. 1998 Aug;21(8):1288-94.PMID: 9702435 [PubMed - indexed for MEDLINE]Related articlesFree article

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.

Diabetes Obes Metab. 2006 Nov;8(6):650-60.PMID: 17026489 [PubMed - indexed for MEDLINE]Related articles

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O; RIO-Europe Study Group.

Eur Heart J. 2008 Jul;29(14):1761-71. Epub 2008 Apr 15.PMID: 18417461 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.

Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.

Clin Ther. 2004 Oct;26(10):1599-607.PMID: 15598476 [PubMed - indexed for MEDLINE]Related articles

Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.

Dibble CT, Gelfand EV, Cannon CP.

Curr Atheroscler Rep. 2007 Nov;9(5):359-66.PMID: 18001618 [PubMed - indexed for MEDLINE]Related articles